RGNX - REGENXBIO Inc.
NEXT EARNINGS:
May 11, 2026
EPS Est: $-1.36
|
Rev Est: $25.8M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$26.00
DETAILS
HIGH:
$45.00
LOW:
$12.00
MEDIAN:
$23.50
CONSENSUS:
$26.00
UPSIDE:
235.05%
Market Cap:
400.52M
Volume:
629,929
Avg Volume:
1,005,781
52 Week Range:
5.035-16.19
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.14
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
353
IPO Date:
2015-09-17
EPS (TTM):
-3.76
P/E Ratio:
-3.83
Revenue (TTM):
170.44M
Total Assets:
453.03M
Total Debt:
260.52M
Cash & Equiv:
34.47M
Rev Growth (5Y):
2.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-48.1%
Debt/Equity:
2.54
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-03-05 | $-1.30 | $-1.01 | -28.7% | $30.3M | $44.0M | -31.0% |
| 2025-11-06 | $-1.20 | $-1.38 | +13.0% | $29.7M | $59.3M | -49.8% |
| 2025-08-07 | $-1.38 | $-1.13 | -22.1% | $21.4M | $110.0M | -80.6% |
| 2025-05-12 | $0.12 | $0.41 | -70.7% | $89.0M | $105.4M | -15.5% |
| 2025-03-13 | $-1.01 | $-1.27 | +20.5% | $21.2M | $23.7M | -10.5% |
| 2024-11-06 | $-1.17 | $-1.16 | -0.9% | $24.2M | $23.4M | +3.2% |
| 2024-08-01 | $-1.05 | $-1.29 | +18.6% | $22.3M | $24.3M | -8.4% |
| 2024-05-08 | $-1.38 | $-1.28 | -7.8% | $15.6M | $23.5M | -33.6% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 170.44M | 83.33M | 90.24M | 112.72M | 470.35M | 154.57M | 35.23M | 218.50M | 10.39M | 4.59M | 7.59M | 6.12M |
| Net Income | (193.88M) | (227.10M) | (263.49M) | (280.32M) | 127.84M | (111.25M) | (94.73M) | 99.94M | (73.17M) | (62.97M) | (22.81M) | (4.00M) |
| EPS | -3.76 | -4.59 | -6.02 | -6.50 | 3.01 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 | -2.49 | -0.30 |
| Total Assets | 453.03M | 465.99M | 573.97M | 833.27M | 1.11B | 708.16M | 497.91M | 543.81M | 198.68M | 172.73M | 221.38M | 3.49M |
| Total Debt | 260.52M | 82.03M | 89.29M | 94.80M | 86.68M | 72.65M | 11.29M | 5.85M | 0 | 0 | 0 | 2.40M |
| Cash & Equivalents | 34.47M | 57.53M | 34.52M | 96.95M | 345.21M | 338.43M | 69.51M | 75.56M | 46.66M | 24.84M | 54.12M | 1.12M |
| Operating Cash Flow | (123.96M) | (173.12M) | (218.41M) | (207.49M) | 218.88M | (54.06M) | (107.70M) | 104.65M | (57.99M) | (48.56M) | (22.52M) | (2.40M) |
| Free Cash Flow | (126.38M) | (175.56M) | (228.37M) | (238.21M) | 134.70M | (80.93M) | (119.42M) | 91.37M | (65.15M) | (56.71M) | (23.04M) | (2.40M) |
| FCF per Share | -2.45 | -3.55 | -5.22 | -5.52 | 3.17 | -2.17 | -3.25 | 2.50 | -2.18 | -2.15 | -2.51 | -0.18 |
| Book Value | 102.73M | 259.65M | 311.74M | 516.20M | 764.30M | 377.75M | 450.20M | 508.85M | 183.03M | 161.74M | 216.81M | (5.70M) |
| Cash & ST Investments | 230.07M | 234.69M | 275.26M | 364.64M | 457.44M | 475.74M | 296.21M | 319.76M | 160.78M | 89.55M | 114.14M | 1.12M |
| ROC Equity | -1.89 | -0.87 | -0.85 | -0.54 | 0.17 | -0.29 | -0.21 | 0.20 | -0.40 | -0.39 | -0.11 | N/A |